Objectives: Graft-versus-host disease is a major problem after bone marrow transplant. GSTO1, GSTO1, and GSTO2 are important genes that interfere with xenobiotic and drug metabolism. Polymorphisms of these genes may influence the metabolism of immunosuppressive drugs given for inhibition of graft-versus-host disease and may influence their susceptibility to diseases, which bone marrow transplant could alleviate.
Materials and Methods:We examined the polymorphisms of 2 groups: The first group was composed of 88 patients who had undergone a bone marrow transplant and 100 otherwise healthy persons; the second group was composed of 54 patients without graft-versus-host disease and 34 patients with graftversus-host disease. We used polymerase chain reaction-restriction fragment length polymorphism method for genotyping GSTO2 and also for multiplexing polymerase chain reactions for GSTO1 and GSTO1 genotypes. Results: No significant association existed between the genotypes GSTO2 (DD: P = .458, OR 0.422), GSTO1 (P = .349, OR 1.52), or GSTO1 (P = .887, OR 1.086), and the incidence of GVHD. Moreover, we saw no association between these polymorphisms and the problems that lead to bone marrow transplant (GSTO2: DD, P = .181, OR 0.465; GSTO1: P = .699, OR 0.892; GSTO1: P = .656, OR 0.845). We showed that men have more bone marrow transplants than do women (P = .019, OR 2.034). Conclusions: Our results show that these polymorphisms may have no effect on the metabolism of drugs used to treat graft-versus-host disease and also, may play no significant role in creating the problems that lead to bone marrow transplant.